4.5 Review

Is It Time to Bring Back Knee Washout?

Journal

JOURNAL OF RHEUMATOLOGY
Volume 49, Issue 12, Pages 1307-1314

Publisher

J RHEUMATOL PUBL CO
DOI: 10.3899/jrheum.211132

Keywords

arthroscopy; arthritis; crystal arthropathies; knee; osteoarthritis; therapeutic irrigation

Categories

Ask authors/readers for more resources

Washing out knee joint contents can remove inflammatory material and be useful for management of various types of arthritis.
Washout of knee joint contents, whether by arthrotomy, arthroscopy, or percutaneous methods, can remove phlogistic material contributing to the problem at hand. Observations dating from the turn of the last century coupled with multiple trials suggest such that an intervention can be useful in the management of osteoar-thritis, inflammatory arthropathies, crystal arthritis, and septic arthritis. We suggest that this intervention- applicable at the bedside with minimal cost, preparation, or expertise-be reconsidered as an adjunct in management of these disorders.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Rheumatology

Evaluating the Construct of Damage in Systemic Lupus Erythematosus

Sindhu R. Johnson, Dafna D. Gladman, Hermine Brunner, David Isenberg, Ann E. Clarke, Megan R. W. Barber, Laurent Arnaud, Paul R. Fortin, Marta Mosca, Alexandre E. Voskuyl, Susan Manzi, Cynthia Aranow, Anca Askanase, Graciela S. Alarcon, Sang-Cheol Bae, Nathalie Costedoat-Chalumeau, Jessica A. English, Guillermo J. Pons-Estel, Bernardo A. Pons-Estel, Rebecca Gilman, Ellen M. Ginzler, John G. Hanly, Soren Jacobsen, Kenneth Kalunian, Diane L. Kamen, Chynace Lambalgen, Alexandra Legge, S. Sam Lim, Anselm Mak, Eric F. Morand, Christine A. Peschken, Michelle Petri, Anisur Rahman, Rosalind Ramsey-Goldman, John A. Reynolds, Juanita Romero-Diaz, Guillermo Ruiz-Irastorza, Jorge Sanchez-Guerrero, Elisabet Svenungsson, Zahi Touma, Murray Urowitz, Evelyne Vinet, Ronald F. van Vollenhoven, Heather Waldhauser, Daniel J. Wallace, Asad Zoma, Ian N. Bruce

Summary: The SLICC, ACR, and Lupus Foundation of America are developing a revised SLE damage index (SDI) due to shifts in the concept of damage in SLE. A qualitative study was conducted to evaluate contemporary constructs in SLE damage and develop a conceptual framework for the revised SDI.

ARTHRITIS CARE & RESEARCH (2023)

Article Rheumatology

High incidence of proliferative and membranous nephritis in SLE patients with low proteinuria in the Accelerating Medicines Partnership

Philip M. Carlucci, Jessica Li, Andrea Fava, Kristina K. Deonaraine, David Wofsy, Judith A. James, Chaim Putterman, Betty Diamond, Anne Davidson, Derek M. Fine, Jose Monroy-Trujillo, Mohamed G. Atta, Wade DeJager, Joel M. Guthridge, Kristin Haag, Deepak A. Rao, Michael B. Brenner, James A. Lederer, William Apruzzese, H. Michael Belmont, Peter M. Izmirly, Devyn Zaminski, Ming Wu, Sean Connery, Fernanda Payan-Schober, Richard Furie, Maria Dall'Era, Kerry Cho, Diane Kamen, Kenneth Kalunian, Jennifer Anolik, Jennifer Barnas, Mariko Ishimori, Michael H. Weisman, Jill P. Buyon, Michelle Petri

Summary: This study found that despite an inactive sediment or normal serologies, three-quarters of patients with UPCR <1 revealed histology showing class III, IV, V or mixed with accompanying activity and chronicity. These data support renal biopsy at thresholds lower than a UPCR of 1.

RHEUMATOLOGY (2022)

Meeting Abstract Rheumatology

EVALUATING THE HYPERSENSITIVITY PROFILE OF ANIFROLUMAB AND THE NEED FOR PREINFUSION PROPHYLACTIC TREATMENT IN PATIENTS WITH SLE

K. C. Kalunian, Y. Tanaka, I. Hupka, L. J. Zhang, M. Shroff, S. Werther, G. Abreu, C. Lindholm, R. Tummala

ANNALS OF THE RHEUMATIC DISEASES (2022)

Article Rheumatology

Phase 3, multicentre, randomised, placebo-controlled study evaluating the efficacy and safety of ustekinumab in patients with systemic lupus erythematosus

Ronald F. van Vollenhoven, Kenneth C. Kalunian, Thomas Doerner, Bevra H. Hahn, Yoshiya Tanaka, Robert M. Gordon, Cathye Shu, Kaiyin Fei, Sheng Gao, Loqmane Seridi, Patrick Gallagher, Kim Hung Lo, Pamela Berry, Qing C. Zuraw

Summary: This study evaluated the efficacy and safety of ustekinumab in patients with active systemic lupus erythematosus (SLE). The results showed that ustekinumab did not demonstrate superiority over placebo in terms of efficacy, and there were no significant differences in adverse events between the treatment groups.

ANNALS OF THE RHEUMATIC DISEASES (2022)

Meeting Abstract Rheumatology

EFFICACY OF BIIB059 ON SKIN MANIFESTATIONS IN PARTICIPANTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) IN THE PHASE 2 LILAC STUDY (PART A)

R. van Vollenhoven, R. Furie, V. Werth, K. Kalunian, X. Huang, C. Musselli, C. Barbey, N. Franchimont

ANNALS OF THE RHEUMATIC DISEASES (2022)

Meeting Abstract Rheumatology

EFFICACY AND SAFETY OF BARICITINIB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS FROM TWO RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 3 STUDIES

E. F. Morand, Y. Tanaka, R. Furie, E. Vital, R. van Vollenhoven, K. Kalunian, M. Mosca, T. Doerner, D. J. Wallace, M. Silk, C. Dickson, I. De la Torre, G. Meszaros, B. Jia, B. Crowe, M. A. Petri

ANNALS OF THE RHEUMATIC DISEASES (2022)

Article Rheumatology

Assessing the Costs of Neuropsychiatric Disease in the Systemic Lupus International Collaborating Clinics Cohort Using Multistate Modeling

Ann E. Clarke, John G. Hanly, Murray B. Urowitz, Yvan St. Pierre, Caroline Gordon, Sang-Cheol Bae, Juanita Romero-Diaz, Jorge Sanchez-Guerrero, Sasha Bernatsky, Daniel J. Wallace, David A. Isenberg, Anisur Rahman, Joan T. Merrill, Paul R. Fortin, Dafna D. Gladman, Ian N. Bruce, Michelle Petri, Ellen M. Ginzler, Mary Anne Dooley, Rosalind Ramsey-Goldman, Susan Manzi, Andreas Jonsen, Graciela S. Alarcon, Ronald F. Van Vollenhoven, Cynthia Aranow, Meggan Mackay, Guillermo Ruiz-Irastorza, S. Sam Lim, Murat Inanc, Kenneth C. Kalunian, Soren Jacobsen, Christine A. Peschken, Diane L. Kamen, Anca Askanase, Vernon Farewell

Summary: The objective of this study was to estimate the costs associated with neuropsychiatric events in SLE. The study found that new/ongoing SLE or non-SLE NP events incurred higher direct and indirect costs. Indirect costs exceeded direct costs by 3.0 to 5.2 fold.

ARTHRITIS CARE & RESEARCH (2023)

Article Rheumatology

A Randomized, Placebo-Controlled Phase III Extension Trial of the Long-Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus Erythematosus

Kenneth C. Kalunian, Richard Furie, Eric F. Morand, Ian N. Bruce, Susan Manzi, Yoshiya Tanaka, Kevin Winthrop, Ihor Hupka, Lijin Jinny Zhang, Shanti Werther, Gabriel Abreu, Micki Hultquist, Raj Tummala, Catharina Lindholm, Hussein Al-Mossawi

Summary: This study investigates the long-term safety and tolerability of anifrolumab 300 mg compared with placebo in patients with systemic lupus erythematosus (SLE). The results show that anifrolumab is well-tolerated and has a favorable benefit-risk profile in patients with moderate-to-severe SLE receiving standard therapy.

ARTHRITIS & RHEUMATOLOGY (2023)

Article Rheumatology

Machine learning identifies clusters of longitudinal autoantibody profiles predictive of systemic lupus erythematosus disease outcomes

May Yee Choi, Irene Chen, Ann Elaine Clarke, Marvin J. Fritzler, Katherine A. Buhler, Murray Urowitz, John Hanly, Yvan St-Pierre, Caroline Gordon, Sang-Cheol Bae, Juanita Romero-Diaz, Jorge Sanchez-Guerrero, Sasha Bernatsky, Daniel J. Wallace, David Alan Isenberg, Anisur Rahman, Joan T. Merrill, Paul R. Fortin, Dafna D. Gladman, Ian N. Bruce, Michelle Petri, Ellen M. Ginzler, Mary Anne Dooley, Rosalind Ramsey-Goldman, Susan Manzi, Andreas Jonsen, Graciela S. Alarcon, Ronald F. van Vollenhoven, Cynthia Aranow, Meggan Mackay, Guillermo Ruiz-Irastorza, Sam Lim, Murat Inanc, Kenneth Kalunian, Soren Jacobsen, Christine Peschken, Diane L. Kamen, Anca Askanase, Jill P. Buyon, David Sontag, Karen H. Costenbader

Summary: A novel longitudinal clustering technique was used to analyze comprehensive autoantibody data from a large, well-characterised, multinational inception SLE cohort, in order to determine predictive profiles of clinical outcomes.

ANNALS OF THE RHEUMATIC DISEASES (2023)

Article Medicine, General & Internal

Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II)

Michelle Petri, Ian N. Bruce, Thomas Doerner, Yoshiya Tanaka, Eric F. Morand, Kenneth C. Kalunian, Mario H. Cardiel, Maria E. Silk, Christina L. Dickson, Gabriella Meszaros, Lu Zhang, Bochao Jia, Youna Zhao, Conor J. McVeigh, Marta Mosca

Summary: Baricitinib, an oral inhibitor of Janus kinase 1 and 2, was evaluated as a treatment for patients with systemic lupus erythematosus (SLE) in a 52-week phase 3 study. The study found that baricitinib did not significantly improve SLE disease activity compared with placebo, and there were no new safety concerns.

LANCET (2023)

Article Rheumatology

Meeting report: the ALPHA project: a stakeholder meeting on lupus clinical trial outcome measures and the patient perspective

Joy Buie, Lauren Bloch, Eric F. Morand, Ronald F. van Vollenhoven, Victoria P. Werth, Zahi Touma, Peter Lipsky, Kenneth Kalunian, Anca D. Askanase, L. Ines, Christopher Reed, MaryBeth Son, Timothy Franson, Karen Costenbader, Laura Eve Schanberg

Summary: Drug development in lupus has improved but lags behind other rheumatic diseases. Challenges in assessing lupus therapies include disease heterogeneity, study design limitations, and lack of validated biomarkers impacting regulatory decision-making. The meeting report addresses the need for standardized outcome measures to accelerate lupus therapeutics development and highlights ongoing efforts in outcome measure development.

LUPUS SCIENCE & MEDICINE (2023)

Article Rheumatology

Infection-related hospitalisation in young adults with systemic lupus erythematosus: data from the National Inpatient Sample

Rashmi Dhital, Monica Guma, Dilli R. Poudel, Christina Chambers, Kenneth Kalunian

Summary: Care of young adults with SLE is challenging due to major life transitions co-occurring with chronic healthcare needs. This study found that young adults with SLE had higher rates of serious infection-related hospitalization compared to adults with SLE and young adults without SLE. Race/ethnicity and comorbidities were associated with hospitalization in young adults with SLE.

LUPUS SCIENCE & MEDICINE (2023)

Article Rheumatology

Association Between Severe Nonadherence to Hydroxychloroquine and Systemic Lupus Erythematosus Flares, Damage, and Mortality in 660 Patients From the SLICC Inception Cohort

Yann Nguyen, Benoit Blanchet, Murray B. Urowitz, John G. Hanly, Caroline Gordon, Sang-Cheol Bae, Juanita Romero-Diaz, Jorge Sanchez-Guerrero, Ann E. Clarke, Sasha Bernatsky, Daniel J. Wallace, David A. Isenberg, Anisur Rahman, Joan T. Merrill, Paul R. Fortin, Dafna D. Gladman, Ian N. Bruce, Michelle Petri, Ellen M. Ginzler, Mary Anne Dooley, Rosalind Ramsey-Goldman, Susan Manzi, Andreas Joensen, Graciela S. Alarcon, Ronald F. Van Vollenhoven, Cynthia Aranow, Veronique Le Guern, Meggan Mackay, Guillermo Ruiz-Irastorza, S. Sam Lim, Murat Inanc, Kenneth C. Kalunian, Soren Jacobsen, Christine A. Peschken, Diane L. Kamen, Anca Askanase, Jill Buyon, Nathalie Costedoat-Chalumeau

Summary: The study aimed to assess the association between severe nonadherence to hydroxychloroquine (HCQ), analyzed by HCQ serum levels, and risks of systemic lupus erythematosus (SLE) flares, damage, and mortality rates. Severe nonadherence was found to be independently associated with increased risk of SLE flares, early damage, and five-year mortality.

ARTHRITIS & RHEUMATOLOGY (2023)

Article Health Care Sciences & Services

Real-world treatment utilization and economic implications of lupus nephritis disease activity in the United States

Maria Dall'Era, Kenneth Kalunian, Michael Eaddy, Augustina Ogbonnaya, Eileen Farrelly, Eric Turowski, Vanessa Birardi, Neil Solomons, Simrat Randhawa, Paola Mina-Osorio

Summary: This study aimed to evaluate treatment utilization and health care costs associated with active disease, low disease activity, and end-stage renal disease (ESRD) in patients with lupus nephritis (LN). The results showed that the treatment burden and costs were high for patients with active disease and ESRD, and treatments that allow patients to achieve and maintain low disease activity may help improve patient outcomes and reduce overall health care costs.

JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY (2023)

No Data Available